<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-two patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) were treated with immunosuppressive therapy (IS) consisting of one or more courses of the following regimens: a) high dose bolus <z:chebi fb="0" ids="50366">6 methylprednisolone</z:chebi> (BMPr); b) horse antilymphocytic globulin (HALG); c) rabbit ALG (RALG); d) ALG followed by the infusion of haploidentical marrow (ALG +/- BM); e) BMPr in combination with HALG; f) ALG in combination with <z:chebi fb="5" ids="50113">androgens</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received one initial course of IS: 16 (38%) showed hematologic reconstitution and required no further transfusions, of 26 refractory patients 4 died, and 22 received a second course of IS 60 days after the first course </plain></SENT>
<SENT sid="2" pm="."><plain>Of these 22, 6 (27%) responded, and of the 16 refractory patients, 9 died, and 7 received a third course of IS 60 days after the second course </plain></SENT>
<SENT sid="3" pm="."><plain>Two of these responded (28%), 3 died and 2 are alive but pancytopenic </plain></SENT>
<SENT sid="4" pm="."><plain>The overall response rate is 24/42 patients (57%): <z:hpo ids='HP_0000001'>all</z:hpo> of these patients are transfusion independent 6-60 months post-treatment, and 17 are off maintenance therapy with low dose steroids </plain></SENT>
<SENT sid="5" pm="."><plain>The actuarial 5 year survival is currently 60%; 13/26 surviving patients have been followed for more than 3 years </plain></SENT>
<SENT sid="6" pm="."><plain>The present study confirms that over 50% of patients with SAA can recover from their <z:mpath ids='MPATH_58'>aplasia</z:mpath> following IS treatment, and this is of relevance for patients who can not be offered a bone marrow transplant </plain></SENT>
</text></document>